<DOC>
	<DOC>NCT00088621</DOC>
	<brief_summary>A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia</brief_summary>
	<brief_title>A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia</brief_title>
	<detailed_description>Study will evaluate long-term safety and tolerability of a new compound in the treatment of patients with schizophrenia as assessed by adverse events (AEs), measures of extra pyramidal symptoms (EPS; Abnormal Involuntary Movement Scale [AIMS], Barnes Akathisia Scale [BAS], and Simpson-Angus Rating Scale [SAS]), vital sign measurements, electrocardiograms (ECGs), clinical laboratory evaluations.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Patients must have participated in study D1050196 (A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia) and either: Successfully completed OR Patients must have been discontinued after a minimum of 2 weeks of treatment due to lack of efficacy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Latuda</keyword>
	<keyword>Lurasidone</keyword>
</DOC>